Neoadjuvant Concurrent Chemoradiation for High-Risk Adult Soft Tissue Sarcoma - 19 Years of a Single Institution Experience


  • Tomás Cabral Dinis ULS de Coimbra
  • Margarida Borrego


Sarcoma; Radioterapia; Quimioterapia; Terapêutica Neoadjuvante.


Introduction: Although Surgery and Radiation therapy (RT) represent standard therapy in High-Risk Soft Tissue Sarcomas (HRSTS), its sequence remains controversial. Neoadjuvant chemoradiation improves survival in patients with HRSTS. Tumor size, surgical margins, and pathologic complete response (pCR) are prognostic factors with unknown significance.
Material and Methods: Retrospective analysis of 25 patients with stage III HRSTS, who underwent neoadjuvant treatment (2002-2020), with 16 receiving preoperative chemoradiation (Adriamycin 90mg/m2 + Dacarbazine 900mg/m2 + Ifosfamide 10mg/m2 ± Vincristin 2mg bolus; 4500-5400cGy/25-30fr) and surgery. Clinical and pathologic data and treatment-related toxicities were assessed. Survival and univariate analyses were performed using Kaplan-Meier Method and Cox regression (a=0.05).
Results: Sixteen patients were included: 68.8% male, median age 44 [18-78] years. Median tumor size was 12 [5-25] cm and 68.8% were extremity sarcomas. Four (25%) patients had pleomorphic liposarcoma and 25% spindle cell sarcomas. Most patients (87.5%) had high grade (G3) tumors. No patient interrupted RT. Median of 7 [5-10] chemotherapy cycles, with cycle postponement in 18.8% patients. Surgery (75% wide excision) occurred on a median of 2 [1-9] months after RT and was uncomplicated in 68.8% (25% wound dehiscence, 12.5% wound necrosis and 6.3% osteitis). Fourteen (87.5%) patients presented negative surgical margins (R0) and 25% pathologic complete response (pCR), with 60% of resected specimens showing ≥90% pathologic necrosis. Eight (50%) patients had hematological toxicity G3-4: 18.8% anemia; 50% leukopenia; 25% thrombocytopenia. Eleven (68.8%) patients presented radiation-induced dermatitis (62.5%, G1-2). For a median follow-up time of 6.3 years [8 months – 18 years], 3 and 5-year survival rates were: Overall Survival and Disease-Free Survival were equivalent (62.5% and 56.3%); Local Recurrence-Free Survival (LRFS) of 92.9%; Distant Disease-Free Survival of 68.8% and 61.9%; Disease-Specific Survival of 75% and 67.5%, respectively. Microscopic positive margins influenced LRFS (50% vs 100%; p=0.014). DSS was non-significantly influenced by pCR (p=0.161) and largest tumor dimension≤10cm (p=0.332).
Conclusion: Neoadjuvant chemoradiation is an acceptable strategy in HRSTS, with comparable survivals to reported data and manageable acute toxicity. Complete resection rates were high and associated with improved LRFS. Smaller tumors (≤10cm) and achieving pCR appears to be favorable prognostic factors.


Não há dados estatísticos.


Armstrong SA, Bishop AJ, Bui MM, Carr-Ascher J, Choy E, Connelly M, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Soft Tissue Sarcoma Version 3.2023 © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed 01/30/2024. To view the most recent and complete version of the guideline, go online to

Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S,et al. ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Nov;32(11):1348-1365. doi: 10.1016/j.annonc.2021.07.006. Epub 2021 Jul 22. PMID: 34303806

Salerno KE, Alektiar KM, Baldini EH, Bedi M, Bishop AJ, Bradfield L, et al. Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2021 Sep-Oct;11(5):339-351. doi: 10.1016/j.prro.2021.04.005. Epub 2021 Jul 26. PMID: 34326023

Wang D, Abrams RA. Radiotherapy for soft tissue sarcoma: 50 years of change and improvement. Am Soc Clin Oncol Educ Book. 2014:244-51. doi: 10.14694/EdBook_AM.2014.34.244. PMID: 24857082

Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014 Sep;260(3):416-21; discussion 421-2. doi: 10.1097/SLA.0000000000000869. PMID: 25115417; PMCID: PMC4170654.

Baldini EH, Le Cesne A, Trent JC. Neoadjuvant Chemotherapy, Concurrent Chemoradiation, and Adjuvant Chemotherapy for High-

Risk Extremity Soft Tissue Sarcoma. Am Soc Clin Oncol Educ Book. 2018May 23;38:910-915. doi: 10.1200/EDBK_201421. PMID: 30231383

Palassini E, Ferrari S, Verderio P, De Paoli A, Martin Broto J, Quagliuolo V, et al. Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide. J Clin Oncol. 2015 Nov 1;33(31):3628-34. doi: 10.1200/JCO.2015.62.9394. Epub 2015 Sep 8. PMID: 26351345

Rosenberg LA, Esther RJ, Erfanian K, Green R, Kim HJ, Sweeting R, Tepper JE. Wound complications in preoperatively irradiated softtissue

sarcomas of the extremities. Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):432-7. doi: 10.1016/j.ijrobp.2012.04.037. Epub 2012 Jun 5. PMID: 22677371; PMCID: PMC4166615

Look Hong NJ, Hornicek FJ, Harmon DC, Choy E, Chen YL, Yoon SS, et al. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. Eur J Cancer. 2013 Mar;49(4):875-83. doi:10.1016/j.ejca.2012.10.002. Epub 2012 Oct 22. PMID: 23092789; PMCID: PMC3777719

Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, et al. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol. 2020 Jul 1;38(19):2178-2186. doi: 10.1200/JCO.19.03289. Epub 2020 May 18. PMID: 32421444

Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer. 2010 Oct 1;116(19):4613-21. doi: 10.1002/cncr.25350. PMID: 20572040; PMCID: PMC3780573

Chowdhary M, Sen N, Jeans EB, Miller L, Batus M, Gitelis S, et al. Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity. Am J Clin Oncol. 2019 Jan;42(1):1-5. doi: 10.1097/COC.0000000000000467. PMID: 29782358

Ouyang Z, Trent S, McCarthy C, Cosker T, Stuart R, Pratap S, et al. The incidence, risk factors and outcomes of wound complications after preoperative radiotherapy and surgery for high grade extremity soft tissue sarcomas: A 14-year retrospective study. Eur J Surg Oncol. 2023 Nov;49(11):107086. doi: 10.1016/j.ejso.2023.107086. Epub 2023 Sep 16. PMID: 37741042.

Wang D, Zhang Q, Eisenberg BL, Kane JM, Li XA, Lucas D, et al. Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology

Group RTOG-0630 Trial. J Clin Oncol. 2015 Jul 10;33(20):2231-8. doi: 10.1200/JCO.2014.58.5828. Epub 2015 Feb 9. PMID: 25667281; PMCID: PMC4486342

Wang D, Harris J, Kraybill WG, Eisenberg B, Kirsch DG, Ettinger DS, et al. Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials. JAMA Oncol. 2023 May 1;9(5):646-655. doi: 10.1001/jamaoncol.2023.0042. PMID: 36995690; PMCID: PMC10064284

DeLaney TF, Spiro IJ, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, et. al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27. doi: 10.1016/s0360-3016(03)00186-x. PMID: 12829150

Spolverato G, Callegaro D, Gronchi A. Defining Which Patients Are at High Risk for Recurrence of Soft Tissue Sarcoma. Curr Treat

Options Oncol. 2020 May 27;21(7):56. doi: 10.1007/s11864-020-00753-9. PMID: 32462511

O’Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in softtissue

sarcoma of the limbs: a randomised trial. Lancet. 2002 Jun 29;359(9325):2235-41. doi: 10.1016/S0140-6736(02)09292-9. PMID: 12103287




Como Citar

Cabral Dinis, T., & Borrego, M. (2024). Neoadjuvant Concurrent Chemoradiation for High-Risk Adult Soft Tissue Sarcoma - 19 Years of a Single Institution Experience. Revista Portuguesa De Oncologia, 7(1-2), 18–24. Obtido de



Artigos de investigação original